Association of loss of heterozygosity with shorter survival in primary glioblastoma patients.

Loss of heterozygosity (LOH) co-deletion 1p/19q, MGMT promoter methylation and/or IDH1 mutation generally signify a better prognosis for patients with glioma. However, the influence of 1p/19q co-deletion and the LOH on other chromosomes in primary glioblastoma on survival is still debatable. The aim of our study was to identify LOH on chromosomes 1p, 19q, 9p, 10q, 13q, and 17p, and evaluate their impact either alone or 1p/19q co-deletion or by groups of LOH on the overall survival of 42 primary glioblastoma patients without an oligodendroglial component. These patients were additionally molecularly characterized for EGFR amplification, IDH1 mutations and TP53 mutations. We assessed their influence on the overall survival of glioblastoma patients. LOH in at least one of the loci on all examined chromosomes was detected in 65% of cases and was significantly associated with shorter overall survival (hazard ratio 3.07; 95% CI: 1.29-7.31, p = 0.006). 1p/19q co-deletion was infrequent (7.14%) and had no impact on overall survival. Our results indicate that in primary glioblastoma a specific LOH group analysis may be important for the prognosis. LOH 1p/19q co-deletion is rare in glioblastoma without an oligodendroglial component and has no impact on patient survival.

[1]  K. Aldape,et al.  Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution , 2013, Modern Pathology.

[2]  M. Karsy,et al.  Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features. , 2012, Folia neuropathologica.

[3]  P. Kleihues,et al.  The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.

[4]  Karsten Wrede,et al.  DMBT1 Homozygous Deletion in Diffuse Astrocytomas Is Associated With Unfavorable Clinical Outcome , 2012, Journal of neuropathology and experimental neurology.

[5]  R. Mirimanoff,et al.  Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial , 2012, Acta Neuropathologica.

[6]  M. Moskała,et al.  Co-occurrence of MGMT gene promoter methylation and amplification of EGFR in glioblastoma , 2011 .

[7]  P. Birner,et al.  Expression of mutated isocitrate dehydrogenase-1 in gliomas is associated with p53 and EGFR expression. , 2011, Folia neuropathologica.

[8]  K. Hoang-Xuan,et al.  All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2 , 2010, Neurology.

[9]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[10]  R. Prayson,et al.  Chromosome 1p and 19q Deletions in Glioblastoma Multiforme , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[11]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[13]  R. Delfini,et al.  Cerebral glioblastoma with oligodendrogliomal component: analysis of 36 cases , 2009, Journal of Neuro-Oncology.

[14]  P. Liberski,et al.  Arrested neural and advanced mesenchymal differentiation of glioblastoma cells-comparative study with neural progenitors , 2009, BMC Cancer.

[15]  P. Liberski,et al.  High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations. , 2009, Cancer genetics and cytogenetics.

[16]  L. Chimelli,et al.  Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis , 2008, Virchows Archiv.

[17]  Arie Perry,et al.  Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. , 2007, Archives of pathology & laboratory medicine.

[18]  P. Rieckmann,et al.  Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26) , 2006, BMC Cancer.

[19]  S. Franceschi,et al.  Correlation Among Pathology, Genotype, and Patient Outcomes in Glioblastoma , 2006, Journal of neuropathology and experimental neurology.

[20]  K. Hoang-Xuan,et al.  Prognostic impact of molecular markers in a series of 220 primary glioblastomas , 2006, Cancer.

[21]  N. Sharpless,et al.  INK4a/ARF: a multifunctional tumor suppressor locus. , 2005, Mutation research.

[22]  P. Kleihues,et al.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.

[23]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[24]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[25]  Daniel J Brat,et al.  Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications: On: Impact of Genotype Morphology on the Prognosis of Glioblastoma. Schmidt MC Antweiler S, Urban N, et al. J Neuropathol Exp Neurol 2002;61:321–328. , 2003, Advances in anatomic pathology.

[26]  Guido Reifenberger,et al.  Pten signaling in gliomas. , 2002, Neuro-oncology.

[27]  R. McLendon,et al.  Molecular markers of prognosis in astrocytic tumors , 2002, Cancer.

[28]  Andreas von Deimling,et al.  Impact of Genotype and Morphology on the Prognosis of Glioblastoma , 2002, Journal of neuropathology and experimental neurology.

[29]  K. Hoang-Xuan,et al.  Glioblastomas with an Oligodendroglial Component: A Pathological and Molecular Study , 2001, Journal of neuropathology and experimental neurology.

[30]  D. Louis,et al.  Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. , 2000, Journal of neurosurgery.

[31]  Y. Yonekawa,et al.  Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas , 2000, Journal of neuropathology and experimental neurology.

[32]  Jan Mollenhauer,et al.  DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3–26.1 is deleted in malignant brain tumours , 1997, Nature Genetics.

[33]  Y. Yonekawa,et al.  Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[35]  F. Zindy,et al.  Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest , 1995, Cell.

[36]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[37]  H. Armah.  Prognostic Impact of Molecular Markers in a Series of 220 Primary GlioblastomasHouillier C, Lejeune J, Benouaich-Amiel A, et al (INSERM U711, Paris; Pierre and Marie Curie Univ, Paris; Group Hosp Pitie-Salpetriere, Paris) Cancer 106:2218–2223, 2006§ , 2008 .

[38]  Takaaki Kirino,et al.  Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  A. Mukasa,et al.  Correlation of Histology and Molecular Genetic Analysis of 1 p , 19 q , 10 q , TP 53 , EGFR , CDK 4 , and CDKN 2 A in 91 Astrocytic and Oligodendroglial Tumors 1 , 2002 .

[40]  J. Kuratsu,et al.  Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. , 2001, Journal of neurosurgery.

[41]  Yasuhiro Yonekawa,et al.  Promoter Hypermethylation of the RB1 Gene in Glioblastomas , 2001, Laboratory Investigation.

[42]  Stefano Colella,et al.  Loss of Heterozygosity on Chromosome 10 Is More Extensive in Primary (De Novo) Than in Secondary Glioblastomas , 2000, Laboratory Investigation.